All requests are reviewed by qualified healthcare professionals.
- Email: support@novametabolic.com
- Phone: 555
-
English
English
GLP-1 receptor agonists like semaglutide and tirzepatide represent the most significant advancement in obesity medicine in decades. Clinical trials show average weight reductions of 15–22% body weight — results previously only possible with surgery.
Ozempic
Semaglutide 0.5–1mg once weekly
Wegovy
Semaglutide 2.4mg — FDA obesity approval
Mounjaro
Tirzepatide dual GIP+GLP-1 agonist
Zepbound
Tirzepatide — FDA approved for obesity
Phentermine
Appetite suppressant for short-term use
Vial Formats
Ozempic & Zepbound in clinical vial format
Browse by medication type
Shop by brand name medication
Nova Metabolic connects patients with licensed US healthcare providers who specialize in medically supervised weight management. Our telehealth platform makes it easy to access Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide), and Zepbound without in-person visits. All consultations are private, HIPAA-compliant, and conducted entirely online.
